

www.tajpharma.com

CEFTARVA® T is supplied as sterile powder in glass vial.

CEFTARVA® T IV Injection: Combipack containing sterile Ceftriaxone Sodium USP equivalent to Ceftriaxone Anhydrous 1000mg tazobactam Sodium equivalent to Tazobactam USP 125mg and 10 ml Water for Injection IP for IV injection.

CEPHALOSPORIN ANTIBIOTIC

CEFTARVA-T

(Ceftriaxone Sodium & Tazobactam Sodium 1.125g)

CEPHALOSPORIN ANTIBIOTIC

CEFTARVA-T

(Ceftriaxone Sodium & Tazobactam Sodium 1.125g)

CEFTARVA® T is a sterile, semisynthetic, broad spectrum cephalosporin antibiotic. Tazobactam sodium is a penicillanic acid sulfone Beta-lactamase inhibitor with a structure similar to that of sulbactam & clavulanic acid. It inactivates susceptible Beta-lactamase by irreversibly binding to the catalytic region of the enzyme. The combination of Tazobactam and ceftriaxone sodium CEFTARVA® T is active against all the organisms resistant to Ceftriaxone.

FORMULATIONS AVAILABLE: INJECTION

COMPOSITION

Each vial contains sterile Ceftriaxone Sodium IP equivalent to Ceftriaxone Anhydrous 1000mg tazobactam Sodium equivalent to Tazobactam USP 125mg and 10 ml Water for Injection IP for IV injection.

DOSAGE FORM

Powder for reconstitution (intravenous (I.V)/intramuscular (I.M)).

PHARMACOKINETICS

Ceftriaxone interferes with the biosynthesis of the peptidoglycan component of the bacterial cell wall by binding to and inactivating penicillin-binding proteins (PBPs). Tazobactam is a penicillanic acid sulfone derivative with β -lactamase inhibitory properties. It enhances the activity of β -lactam antibiotics against β -lactamase-producing bacteria.

Distribution

Ceftriaxone: 98% bound to plasma proteins; crosses the blood brain barrier. Tazobactam: About 30% bound to plasma proteins; widely distributed to tissues and body fluids.

Excretion

Ceftriaxone: Elimination half-life is about 8.7 hours; 33-67% removed as unchanged drug. Tazobactam: Removed mainly via kidneys with 80% of an administered dose as unchanged drug.

INDICATIONS

To reduce the development of drug-resistant bacteria and maintain the effectiveness of CEFTARVA® T Injection, it should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria.

CEFTARVA® T Injection is mainly indicated in the following conditions:

Lower respiratory tract infections and community-acquired pneumonia, Acute bacterial otitis media, Skin and skin structure infections, Urinary tract infections, Uncomplicated gonorrhea, Pelvic inflammatory disease, Bacterial septicemia, Bone and joint infections, Intra-abdominal infections, Bacterial meningitis, Pre-operative prophylaxis of infections associated with surgery

CEFTARVA® T (Ceftriaxone Sodium & Tazobactam Sodium 1.125g) : 1000/125 mg once daily or in equally divided doses twice a day.

Food and Drug Administration (FDA) approved .Prescription Only (POM)

A Taj Pharma"India Product